Related Experiment Video

Updated: Nov 15, 2025

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
07:43

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

10.8K

Pembrolizumab monotherapy in metastatic triple-negative breast cancer

Eitan Amir1, David W Cescon1

  • 1Division of Medical Oncology, Princess Margaret Cancer Centre and the University of Toronto, Toronto, ON M5G 2M9, Canada.

The Lancet. Oncology
|March 7, 2021
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
07:42

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

5.4K
Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
09:29

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

18.5K

Related Experiment Videos

Last Updated: Nov 15, 2025

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
07:43

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

10.8K
Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
07:42

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

5.4K
Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
09:29

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

18.5K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.1K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.5K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K

Articles linked to this work by shared authors, journal, and citation graph.

(Neo)adjuvant approvals for solid tumors by the US Food and Drug Administration 2010-2023.

Journal of the National Cancer Institute·2026

The UVA-induced single-base mutational signature of CX-5461 in human cells.

Nucleic acids research·2026

The impact of menopausal status on the efficacy of adjuvant CDK4/6 inhibitors in hormone receptor-positive early breast cancer: a systematic review and meta-analysis of phase III clinical trials.

Breast cancer research and treatment·2026

Cardiovascular Disease in Males With Breast Cancer: A Population-Based Cohort Study.

JACC. Advances·2026

Outcomes in KEYNOTE-355 after chemotherapy discontinuation before pembrolizumab discontinuation and with immune-mediated adverse events.

NPJ breast cancer·2026

Differential Treatment Effects by Smoking Status for NSCLC Therapies (2010-2023): A Meta-Analysis.

JTO clinical and research reports·2026

Patient-reported symptom monitoring in patients with lung cancer (SYMPRO-Lung trial): long-term, post-hoc survival results of a multicentre, stepped-wedged, cluster-randomised clinical trial.

The Lancet. Oncology·2026

Development and external validation of a new prognostic model for metastatic clear cell renal cell carcinoma: a preregistered analysis using data from randomised clinical trials in the checkpoint inhibitor era.

The Lancet. Oncology·2026

Induction and extended consolidation with daratumumab, cyclophosphamide, bortezomib, lenalidomide, and dexamethasone in patients with high-risk multiple myeloma (OPTIMUM/MUKnine): 5-year follow-up of a multicentre, externally controlled, phase 2 trial.

The Lancet. Oncology·2026

Chemotherapy with or without pembrolizumab followed by maintenance pembrolizumab with or without olaparib as first-line treatment of patients with advanced BRCA non-mutated epithelial ovarian cancer (ENGOT-OV43/GOG-3036/KEYLYNK-001): a randomised, double-blind, placebo-controlled, phase 3 trial.

The Lancet. Oncology·2026

An integrated lifestyle intervention for mitigation of adverse effects associated with androgen deprivation therapy for prostate cancer (STAMINA): a multicentre, randomised trial.

The Lancet. Oncology·2026

Challenges in the use of the European Society for Radiotherapy and Oncology-European Organisation for Research and Treatment of Cancer oligometastatic disease classification system in ovarian cancer.

The Lancet. Oncology·2026

Chaetocin Induces Ferroptosis in Cisplatin-Resistant Ovarian Cancer Cells Through Neddylation-Mediated TFRC Upregulation.

Phytotherapy research : PTR·2026

Wogonin targets GATA1 to induce ferroptosis and potentiate cisplatin-mediated anti-tumor effects in esophageal squamous cell carcinoma.

Phytomedicine : international journal of phytotherapy and phytopharmacology·2026

Cartap hydrochloride induces dose-dependent oxidative stress and HSP70 overexpression in testicular tissue of Wistar rats: protective effect of α-tocopherol.

Reproductive toxicology (Elmsford, N.Y.)·2026

Targeting oxaliplatin-induced peripheral neuropathy: neurobiological mechanisms, therapeutic evidence, and translational perspectives.

Neuroscience·2026

Effects of non-pharmacological interventions on chemotherapy-induced taste alterations among cancer patients: A systematic review and meta-analysis.

International journal of nursing studies·2026

Disulfiram reverses fluconazole-resistance mediated by Cdr1 in Candida albicans and interferes with biofilm formation.

Applied microbiology and biotechnology·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us